Vaxart (VXRT) vs. Its Peers Head-To-Head Survey

Vaxart (OTCMKTS:VXRT) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Vaxart to similar companies based on the strength of its profitability, risk, institutional ownership, earnings, dividends, valuation and analyst recommendations.

Analyst Ratings

This is a breakdown of current ratings and price targets for Vaxart and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxart	0	1	0	0	2.00
Vaxart Competitors	7798	13891	25788	1038	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 24.59%. Given Vaxart’s peers stronger consensus rating and higher probable upside, analysts plainly believe Vaxart has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Vaxart and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vaxart	$237.26 million	$16.33 million	2.88
Vaxart Competitors	$5.43 billion	$3.22 billion	552.60

Vaxart’s peers have higher revenue and earnings than Vaxart. Vaxart is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Vaxart has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500. Comparatively, Vaxart’s peers have a beta of -3.79, meaning that their average share price is 479% less volatile than the S&P 500.

Institutional and Insider Ownership

18.0% of Vaxart shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 2.8% of Vaxart shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Vaxart and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxart	16.02%	35.14%	17.10%
Vaxart Competitors	-2,380.39%	-218.78%	-15.59%

Summary

Vaxart peers beat Vaxart on 9 of the 13 factors compared.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.